Literature DB >> 21641064

Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer.

Atsuya Takeda1, Etsuo Kunieda, Toshio Ohashi, Yousuke Aoki, Naoyoshi Koike, Toshiaki Takeda.   

Abstract

PURPOSE: To analyze local control of oligometastatic lung tumors (OLTs) compared with that of primary lung cancer after stereotactic body radiotherapy (SBRT).
MATERIALS AND METHODS: Retrospective record review of patients with OLTs who received SBRT with 50Gy in 5 fractions. Local control rates (LCRs), toxicities, and factors of prognostic significance were assessed.
RESULTS: Twenty-one colorectal OLTs, 23 OLTs from other origins, and 188 primary lung cancers were included. Multivariate analysis revealed only tumor origin was prognostically significant (p<0.05). The 1-year/2-year LCRs in colorectal OLTs and OLTs from other origins were 80%/72% and 94%/94%, respectively. The LCR in colorectal OLTs was significantly worse than that in OLTs from the other origins and primary lung cancers with pathological and clinical diagnosis (p<0.05, p<0.0001 and p<0.005). Among 44 OLT patients, Grades 2 and 3 radiation pneumonitis were identified in 2 and 1 patients, respectively. No other toxicities of more than Grade 3 occurred.
CONCLUSION: SBRT for OLTs is tolerable. The LCR for OLTs from origins other than colorectal cancer is excellent. However, LCR for colorectal OLTs is worse than that from other origins. Therefore dose escalation should be considered to achieve good local control for colorectal OLTs.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21641064     DOI: 10.1016/j.radonc.2011.05.033

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  64 in total

1.  Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung.

Authors:  Deepinder Singh; Yuhchyau Chen; Mary Z Hare; Kenneth Y Usuki; Hong Zhang; Thomas Lundquist; Neil Joyce; Michael C Schell; Michael T Milano
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

Review 2.  Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer.

Authors:  Aaron T Wild; Yoshiya Yamada
Journal:  Visc Med       Date:  2017-02-03

3.  Oligometastases to the liver: predicting outcomes based upon radiation sensitivity.

Authors:  Haoming Qiu; Alan W Katz; Michael T Milano
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

4.  Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs).

Authors:  Feras Oskan; Yvonne Dzierma; Stefan Wagenpfeil; Christian Rübe; Jochen Fleckenstein
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 5.  Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer.

Authors:  Atsuya Takeda; Naoko Sanuki; Etsuo Kunieda
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

6.  The debate for thermal ablation of colorectal cancer pulmonary metastases is heating up.

Authors:  Karin Steinke
Journal:  Quant Imaging Med Surg       Date:  2020-05

Review 7.  Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.

Authors:  Neil B Desai; Aaron M Laine; Robert D Timmerman
Journal:  Br J Radiol       Date:  2016-12-23       Impact factor: 3.039

Review 8.  Systemic Versus Local Therapies for Colorectal Cancer Pulmonary Metastasis: What to Choose and When?

Authors:  Tony Ibrahim; Lambros Tselikas; Charbel Yazbeck; Joseph Kattan
Journal:  J Gastrointest Cancer       Date:  2016-09

9.  Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Motohiro Yamashita; Naoyuki Nogami; Yoshifumi Sugawara; Toshiyuki Kozuki; Shigeki Sawada; Hiroshi Suehisa; Syuichi Shinohara; Naomi Nakajima; Tetsu Shinkai
Journal:  Jpn J Radiol       Date:  2012-03-27       Impact factor: 2.374

10.  Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.

Authors:  Rosario Mazzola; Sergio Fersino; Giuseppe Ferrera; Giovanni Targher; Vanessa Figlia; Luca Triggiani; Nadia Pasinetti; Antonio Lo Casto; Ruggero Ruggieri; Stefano Maria Magrini; Filippo Alongi
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.